Genenta Science S.p.A.

GNTA Nasdaq CIK: 0001838716

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type other
SEC Category Non-accelerated filerEmerging growth company
State of Incorporation Italy
Business Address OLGETTINA, NO. 58, MILAN, L6, 20132
Mailing Address OLGETTINA, NO. 58, MILAN, L6, 20132
Phone 39-02-2643-6639
EIN 000000000

Financial Overview

FY2024

Recent SEC Filings

Form Type Date Filed Document
20-F Foreign company annual report April 1, 2026 View on SEC
4 Insider stock transaction report April 1, 2026 View on SEC
4 Insider stock transaction report April 1, 2026 View on SEC
4 Insider stock transaction report April 1, 2026 View on SEC
4 Insider stock transaction report April 1, 2026 View on SEC
4 Insider stock transaction report April 1, 2026 View on SEC
6-K Foreign company current report March 27, 2026 View on SEC
3 Initial insider ownership report March 25, 2026 View on SEC
6-K Foreign company current report March 24, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC

Annual Reports

20-F April 1, 2026
  • Advancing Temferon™ platform through early-stage clinical trials for brain cancer and solid tumors.
  • Maintains strategic research partnerships with Ospedale San Raffaele to optimize treatment production.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.